Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

NCT04781998 · Completed

Last updated 2026-05-28

This clinical trial is testing whether Saxenda® (liraglutide) can be a feasible treatment for weight loss in overweight or obese patients receiving care in forensic psychiatric settings.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 24 people

Who can join Ages 18–65 · all sexes

Timeline Started 2021-07 · est. completion 2022-09

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT04781998 ↗

Description as written by the study sponsor.

An open-label, multi-centre, 26-weeks clinical feasibility study. The objective is to explore whether Saxenda could be a feasible choice in the treatment of overweight, obesity and weight-related medical problems, in patients diagnosed with a severe mental illness and hospitalized at a forensic department in Denmark. We wish to determine the viability of the daily Saxenda®-injection treatment in this specific patient group.

Treatments tested

liraglutide 3 mg (Saxenda®) once-daily Drug

Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.

Main thing measured	The primary endpoint is the number of "completers"
Sponsor	Anders Fink-Jensen, MD, DMSci
Conditions studied	Mental Disorder, Metabolic Disturbance, Feasibility, Overweight and Obesity, Liraglutide
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04781998 ↗